Ernst emphasized the strategic transformation of Tivic into a diversified therapeutics company, combining biologic and bioelectronic approaches to address immune dysregulation. This includes ...
Small-molecule inhibitors targeting viral proteins could serve as an effective alternative for controlling the spread of COVID-19 at both individual and community levels. In this vein, a recent study ...
Novartis receives third FDA approval for oral Fabhalta® (iptacopan) – the first and only treatment approved in C3 glomerulopathy (C3G) Fabhalta is the only oral alternative complement pathway ...
Adma Biologics (ADMA) witnessed a jump in share price last session on above-average trading volume. The latest trend in ...
The database, which Cruz recently released, shows a full list of over 3,400 NSF grants, awarded under the Biden ...
Zacks Investment Research on MSN3d
FDA Accepts RDY & ALVO's Prolia & Xgeva Biosimilar BLA for ReviewDr. Reddy’s Laboratories RDY and partner, Alvotech ALVO, announced the FDA’s acceptance of a regulatory filing, seeking the ...
Dr. Reddy’s Laboratories (RDY) and Alvotech (ALVO) announced that the U.S. FDA has accepted a Biologic License Application submission for AVT03. Read more here.
Significant progress was made in 2024, including refining the Phase 3 program to accelerate rilparencel’s path to market in the U.S., the release ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback